Deciphera Pharmaceuticals
1
52M
1
0.06
1
- Areas of investment
Summary
Deciphera Pharmaceuticals is the famous Corporate Investor, which was founded in 2003. The leading representative office of defined Corporate Investor is situated in the Waltham. The venture was found in North America in United States.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Deciphera Pharmaceuticals Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund.
The fund was created by Michael D. Taylor.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Deciphera Pharmaceuticals, startups are often financed by SV Health Investors, New Leaf Venture Partners. The meaningful sponsors for the fund in investment in the same round are Viking Global Investors, Sphera Global Healthcare Fund, Redmile Group.
The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is generally included in less than 2 deals every year. The high activity for fund was in 2017. The top amount of exits for fund were in 2017.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.06
- Investments by industry
- Pharmaceutical (1)
- Medical (1)
- Therapeutics (1)
- Biotechnology (1)
- Health Care (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 18
- Group Appearance index
- 1.00
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Deciphera Pharmaceuticals | 01 Jun 2017 | Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics | Late Stage Venture | 52M | United States, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.